Tenumomeran/Raplemomeran Plus Pembrolizumab Misses PFS End Point in HPV16+ HNSCC
BioNTech's phase 2/3 trial of BNT113 (tenumomeran/raplemomeran) plus pembrolizumab missed its primary progression-free survival (PFS) endpoint in HPV16+ head and neck cancer. The trial will continue to assess overall survival (OS) as the other primary endpoint. BioNTech received FDA fast track designation for BNT113 in January 2026.
How this was made
The 30-second read
Why it matters
The independent data monitoring committee recommended continuing to assess overall survival after the combination missed the PFS primary endpoint, shifting the market focus from PFS to the remaining OS readout.
Market read
This is a program-level efficacy de-risking event for BioNTech’s HPV16 mRNA combo, with the next decision point tied to overall survival results.
What to watch
The article notes the OS endpoint is still pending and that the trial’s prespecified design could allow a positive outcome despite PFS failure, so investors may be over-weighting the first analysis.
Background
AHEAD-MERIT is an open-label phase 2/3 trial evaluating tenumomeran/raplemomeran (BNT113) plus pembrolizumab versus pembrolizumab alone in first-line unresectable recurrent or metastatic HPV16+ PD-L1 expressing HNSCC.
Ticker impact
BioNTech’s AHEAD-MERIT phase 2/3 shows tenumomeran/raplemomeran plus pembrolizumab failed to significantly improve PFS versus pembrolizumab alone, missing a primary endpoint.
Likely downward pressure as investors price in reduced efficacy risk, partially tempered by the committee’s recommendation to continue for overall survival.
The article reports a primary endpoint miss (PFS) in a randomized phase 2/3, which is typically a material de-risking event; OS is the remaining potential offset but is not yet reported.
Market effects
Adds evidence that mRNA cancer immunotherapy combinations may face efficacy hurdles in HPV16+ HNSCC, potentially affecting sentiment toward similar combo strategies.
Limited direct regional impact; primarily affects US-listed biotech sentiment and clinical-trial risk appetite.
Relevant to global oncology investors tracking checkpoint plus mRNA platform read-through, but not a broad market driver.
Counterpoint
OS could still validate the program if the PFS miss reflects delayed separation or post-progression effects; the trial continues specifically to assess OS.
Key entities
- companyBNTX
BioNTech, sponsor of the AHEAD-MERIT trial and developer of tenumomeran/raplemomeran (BNT113).
- drugKeytruda
Pembrolizumab, the checkpoint inhibitor backbone used in both arms of the trial.
- clinical_trialAHEAD-MERIT (NCT04534205)
Phase 2/3 trial in HPV16+ PD-L1 expressing recurrent or metastatic HNSCC evaluating BNT113 plus pembrolizumab versus pembrolizumab alone.
